India's approval of homegrown vaccine criticised over lack of data

By Krishna N. Das NEW DELHI (Reuters) - India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine. The news, announced by the drugs controller general of India (DCGI), was hailed by Prime Minister Narendra Modi and his ministers as a success in the country's self-reliance push.

Reuters January 04, 2021 00:10:19 IST
India's approval of homegrown vaccine criticised over lack of data

Indias approval of homegrown vaccine criticised over lack of data

By Krishna N. Das

NEW DELHI (Reuters) - India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.

The news, announced by the drugs controller general of India (DCGI), was hailed by Prime Minister Narendra Modi and his ministers as a success in the country's self-reliance push.

The government also approved the use of a vaccine developed by AstraZeneca and Oxford University which will be the lead vaccine in India's immunisation programme.

COVAXIN was jointly developed with a government institute and means India joins a small list of countries to have approved their own coronavirus vaccines.

Bharat Biotech has partnered with drug developer Ocugen Inc to co-develop it for the U.S. market, and Brazil has signed non-binding letters of intent to buy the shot.

The company has said it is in discussions with more than 10 countries about COVAXIN.

"Our goal is to provide global access to populations that need it the most," Bharat Biotech Chairman Krishna Ella said in a statement.

"COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist."

Neither the company nor India's Central Drugs Standards Control Organisation would reveal its efficacy results. A source with knowledge of the matter told Reuters its effectiveness could be more than 60% with two doses.

China also did not publish detailed efficacy data for a vaccine it authorised on Thursday but its developer has shared interim data.

"On what basis was this approval given when Bharat Biotech has NOT shown enough data proving safety & efficacy?" transparency activist Saket Gokhale asked on Twitter.

Gokhale has filed a request under India's right-to-information law asking the government for safety and other data for the two vaccines approved on Sunday.

Serum Institute of India (SII), the local maker of the AstraZeneca shot that will be branded COVISHIELD in the country, also took a dig at the Bharat Biotech vaccine.

"Until we get the efficacy result, how do we know that anything works?" SII Chief Executive Adar Poonawalla told Reuters.

A government scientist said in November COVAXIN might be approved in February or March. It is now likely to be rolled out much earlier following the approval on Sunday.

Opposition lawmakers and former ministers on Sunday questioned the lack of transparency in approving it.

"Approval was premature and could be dangerous," said opposition lawmaker and former minister Shashi Tharoor.

"Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime."

Vardhan urged Indians to trust that "stringent protocols" had been followed for the two approved vaccines.

In the largest such trial in India, Bharat Biotech said it had recruited 23,000 volunteers out of a target of 26,000 for an ongoing Phase III trial of COVAXIN which began in November.

(Additional reporting by Aftab Ahmed and Nigam Prusty; editing by Jason Neely and Alexandra Hudson)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Trump disavows any responsibility for his supporters' Jan. 6 attack
World

Trump disavows any responsibility for his supporters' Jan. 6 attack

By Steve Holland and Andrea Shalal JOINT BASE ANDREWS, Md./WASHINGTON (Reuters) - U.S. President Donald Trump, facing impeachment on a charge of "incitement of insurrection" on Tuesday disavowed responsibility for his supporters' violent invasion of the U.S. Capitol last week and said his remarks before the siege were appropriate.

Renault and Plug Power to develop fuel-cell commerical vehicles
News & Analysis

Renault and Plug Power to develop fuel-cell commerical vehicles

PARIS (Reuters) - French carmaker Renault and U.S. hydrogen specialist Plug Power have joined forces to develop hydrogen-powered light commercial vehicles, they said on Tuesday. The companies have signed a memorandum of understanding to launch a France-based 50-50 joint venture by the end of the first half of 2021, targeting more than 30% share of the fuel cell-powered light commercial vehicle market in Europe, their joint statement said

Analysis: Tesla's Model Y to emerge disruptor as China EV sales zoom in 2021
News & Analysis

Analysis: Tesla's Model Y to emerge disruptor as China EV sales zoom in 2021

By Yilei Sun and Brenda Goh BEIJING/SHANGHAI (Reuters) - New models will help electric vehicle sales in China zoom this year, after tepid business in a virus-riddled 2020, and analysts predict Tesla's Model Y pricing will emerge as a major disruptor in the world's biggest car market. Tesla Inc, which became the world's most valuable car maker last year, started selling locally made Model Y SUVs in China this month, for almost a tenth less than gasoline-powered luxury cars with similar market positioning. It set the starting price at 339,900 yuan ($52,376), or 10% below official prices of Daimler's Mercedes GLC, BMW's X3 and Audi's Q5L - all locally made gasoline sport utility vehicles (SUVs) with similar size and positioning.